A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals

This publication has 28 references indexed in Scilit:

• A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali
  Vaccine, 2009
• Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
  New England Journal of Medicine, 2008
• Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
  PLOS ONE, 2008
• Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses
  PLOS ONE, 2008
• Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines
  Vaccine, 2008
• Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians
  PLOS ONE, 2007
• Structural basis of antigenic escape of a malaria vaccine candidate
  Proceedings of the National Academy of Sciences, 2007
• Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen
  Vaccine, 2007
• Formulation of vaccines containing CpG oligonucleotides and alum
  Journal of Immunological Methods, 2007
• Immunity to RecombinantPlasmodium falciparumMerozoite Surface Protein 1 (MSP1): Protection inAotus nancymaiMonkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity
  Infection and Immunity, 2006